Massachusetts Institute of Technology

E.i. Dupont De Nemours and Company

Therics, Inc.

Fmc Corporation

Chen-Chao Wang

Jaedeok Yoo

Christopher M Gaylo

Donald C Monkhouse

Michael John Cima

Keith A Freehauf

Robert D Simmons

Jill K Sherwood

Frank Guerino

Esteban Bornancini

Francis C Payumo

Roger Mervyn Sargent

Willie J Roach

Qing Wen Liu

Peter A Materna

Thomas George West

Thomas J Bradbury

Henry Leon Surprenant

Timothy J Pryor

Monica Tejwani

Alfred Anthony Litwak

Sunil Saini

Kathleen D Chesmel

Heather Ann Beam

Peter Andrew O'Neil

Jennifer Patterson

Peter Andrew O'Neill

Monica Rewachand Motwani

Keith Alan Freehauf

Peter Andrew O'neil

The present invention provides formulations and methods useful in the control of ectoparasites on a domestic animal, using a formulation comprising Indoxacarb and a veterinarily acceptable carrier that is applied topically to 10% or less of the total surface area of a domestic animal. Other embodiments include these formulations also including one or more additional pesticides such as fipronil.

Local topical administration formulations containing indoxacarb

The invention includes a core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles of a release-regulating polymer. The shell may be substantially impervious but the release-regulating polymer may become suitable to allow diffusion through it when activated. The core may include a buffer region between the shell and the API-containing portion of the core. The dosage form may include multiple units. The dosage form of the invention is capable of providing a release profile whose time scale can be adjusted by adjusting powder composition, and which may be approximately zero-order release. The invention further includes methods of manufacturing such a dosage form, such as three-dimensional printing.

Diffusion-controlled dosage form and method of fabrication including three dimensional printing

A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The drug in the toxic or potent core is incorporated into the dosage form via, for example, three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder. This minimizes the likelihood of creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the hazardous substance. Wet dispensing of the toxic or potent drug further provides greater bioavailability of the drug to the patient.

Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form

An engineered regenerative biostructure (erb) for implantation into a human body as a bone substitute, which includes an internal microstructure, mesostructure and/or macrostructure to provide improved bone in-growth, and methods for making the erb. Under one aspect of the invention, the biostructure has resorbable and nonresorbable regions. Under another aspect of the invention, the biostructure is constructed of hydroxyapatite, tricalcium phosphate and/or demineralized bone. Under yet another aspect of the invention, the porous biostructure is partially or fully infused with a resorbable, nonresorbable or dissolvable material.

Method and apparatus for engineered regenerative biostructures such as hydroxyapatite substrates for bone healing applications

Growing community of inventors

West Windsor, NJ, United States of America

Chen-Chao Wang